Clinical Trial Update: Managed Access Programs for INC424, Ruxolitinib

View source ↗

Summary

Novartis-sponsored update on managed access programs for INC424 (ruxolitinib), outlining eligible indications including primary myelofibrosis, post-polycythemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Myelofibrosis
• Myelofibrosis with Thrombocytosis
• Polycythemia Vera
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Jakafi (ruxolitinib)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF) | Status: AVAILABLE